PHORA-Pulmonary Hypertension Outcome Risk Assessment
- Institution
- SENTARA HEALTH, VA
- Principal investigator
- Raymond Louis Benza
- Funding
- $544K
- Duration
- 2024–2027
Moonbase score
Still being scored
Abstract
ABSTRACT This application seeks to develop improve and expand a multi-platform clinical decision support system (CDSS) in pulmonary arterial hypertension (PAH) for physicians, PHORA (Pulmonary Hypertension Outcomes Risk Assessment), which can be used in adults and children to: a) guide therapeutic decisions and b) optimize clinical trial design. We will achieve this goal by utilizing clinical trial data from several large databases of completed trials in PAH, ongoing adult and Pediatric PAH registries and Biobanks. The proposed aims co-create the CDSS with a multi-disciplinary group of specialties including: biomedical engineering, advanced PAH, computer science (machine learning/data mining), human computer interaction, and palliative care experts. Our intention is to engage all stakeholders to achieve consensus and thereby assure the acceptance of PHORA into practice. Successful completion of this project will lay the foundation for a prospective, multi-center META-Registry in which PHORA will be evaluated with respect to modeling best practice interventions leading to improved long-term patient outcomes. The ultimate aim is to disseminate this resource so as to improve the efficiency, efficacy, and cost-effectiveness of this treatment for PAH.
LOADING MOONBASE SCORE
Questions for Sentara Health
Sentara Health hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same researchers, same topic, scored first.
- NIH · Icahn School of Medicine at Mount SinaiNot yet scored
The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension
Raymond Louis Benza · $336K · 2023–2026
- NIH · University of California, San DiegoNot yet scored
Eicosanoid Pathways Underlying Disease Risk in Pulmonary Arterial Hypertension
Mona A Alotaibi · $174K · 2024–2028
- NIH · Augusta University51
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension
Scott A Barman · $701K · 2016–2026